高级检索
当前位置: 首页 > 详情页

Effect of Hemoglobin A1c Trajectories on Future Outcomes in a 10-Year Cohort With Type 2 Diabetes Mellitus

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China [2]Capital Med Univ, Beijing Tongren Hosp, Dept Endocrinol, Beijing, Peoples R China [3]Capital Med Univ, Beijing Ditan Hosp, Med Records & Stat Dept, Beijing, Peoples R China [4]Cuigezhuang Community Hlth Serv Ctr, Dept Gen Practice, Beijing, Peoples R China [5]Jinsong Community Hlth Serv Ctr, Dept Gen Practice, Beijing, Peoples R China [6]Xinjiekou Community Hlth Serv Ctr, Dept Gen Practice, Beijing, Peoples R China [7]Beijing Aerosp Gen Hosp, Dept Endocrinol, Beijing, Peoples R China [8]Aerosp Cent Hosp, Dept Gen Practice, Beijing, Peoples R China [9]Sanlitun Community Hlth Serv Ctr, Dept Gen Practice, Beijing, Peoples R China [10]Jiangtai Community Hlth Serv Ctr, Dept Gen Practice, Beijing, Peoples R China [11]Majiapu Community Hlth Serv Ctr, Dept Gen Practice, Beijing, Peoples R China
出处:
ISSN:

关键词: clinical outcomes HbA1c-adjSD HbA1c-CV HbA1c trajectories HbA1c variability type 2 diabetes mellitus

摘要:
BackgroundHemoglobin A1c (HbA1c) variability may be a predictor of diabetic complications, but the predictive values of HbA1c trajectories remain unclear. We aimed to classify long-term HbA1c trajectories and to explore their effects on future clinical outcomes in a 10-year cohort with type 2 diabetes mellitus (T2DM). MethodsA total of 2,161 participants with T2DM from the Beijing Community Diabetes Study were included. The 10-year follow-up was divided into two stages for the present data analysis. Stage I (from 2008 to 2014) was used to identify the HbA1c trajectories and to calculate the adjusted SD of HbA1c (HbA1c-adjSD), or the coefficient of variation of HbA1c (HbA1c-CV). Stage II (from 2014 to 2018) was used to collect the records of the new occurrence of diabetes-related clinical outcomes. Latent growth mixture models were used to identify HbA1c trajectories. Cox proportional hazards models were used to explore the relationship between HbA1c trajectories, HbA1c-adjSD, or HbA1c-CV and the future outcomes. ResultsThree HbA1c trajectories were identified, including low stable (88.34%), gradual decreasing (5.83%), and pre-stable and post-increase (5.83%). Either the risk of death or the chronic complications were significantly higher in the latter two groups compared to the low stable group after adjustment for average HbA1c and other traditional risk factors, the adjusted hazard ratios (HRs) for renal events, composite endpoint, and all-cause death for the pre-stable and post-increase group were 2.83 [95%CI: 1.25-6.41, p = 0.013], 1.85 (95%CI: 1.10-3.10, p = 0.020), and 3.01 (95%CI: 1.13-8.07, p = 0.028), respectively, and the adjusted HR for renal events for the gradual decreasing group was 2.37 (95%CI: 1.08-5.21, p = 0.032). In addition, both univariate and multivariate Cox HR models indicated that participants in the fourth and third quartiles of HbA1c-CV or HbA1c-adjSD were at higher risk of renal events compared to participants in the first quartile. ConclusionsHbA1c trajectories, HbA1c-CV, and HbA1c-adjSD could all predict diabetes-related clinical outcomes. HbA1c trajectories could reflect long-term blood glucose fluctuation more intuitively, and non-stable HbA1c trajectories may predict increased risk of renal events, all-cause death, and composite endpoint events, independent of average HbA1c.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 内分泌学与代谢
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 内分泌学与代谢
JCR分区:
出版当年[2020]版:
Q1 ENDOCRINOLOGY & METABOLISM
最新[2023]版:
Q2 ENDOCRINOLOGY & METABOLISM

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21166 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)